President’s Budget Calls For Unrestricted Biosimilar Switching

The president’s budget proposal for fiscal 2025 includes a proposal to allow pharmacy substitution of biosimilar drugs without an interchangeability designation, but FDA Commissioner Robert Califf said approval from Congress is still the best pathway to making the change. The proposal is one of many drug cost-cutting policies included in the Biden administration’s budget request , unveiled Monday (March 11). The budget calls for permitting pharmacists to automatically substitute brands with biosimilars, even those without an FDA determination of interchangeability...